Plasma Growth Hormone as a Prognostic Biomarker to Durvalumab and Tremelimumab in Patients with Advanced Hepatocellular Carcinoma

Plasma Growth Hormone as a Prognostic Biomarker to Durvalumab and Tremelimumab in Patients with Advanced Hepatocellular Carcinoma

Shadi Chamseddine,1,* Michael LaPelusa,2,* Lianchun Xiao,3 Yehia I Mohamed,1 Sunyoung S Lee,1 Zishuo Ian Hu,1 Rikita I Hatia,4 Manal Hassan,4 James C Yao,1 Dan G Duda,5 Saumil Datar,6 Hesham M Amin,7,8 Ahmed O Kaseb1 1Department of Gastrointestinal Medical Oncology, The University of...

Full description

Bibliographic Details
Main Authors: Chamseddine S, LaPelusa M, Xiao L, Mohamed YI, Lee SS, Hu ZI, Hatia RI, Hassan M, Yao JC, Duda DG, Datar S, Amin HM, Kaseb AO
Format: Article
Language:English
Published: Dove Medical Press 2024-03-01
Series:Journal of Hepatocellular Carcinoma
Subjects:
hepatocellular carcinoma
growth hormone
durvalumab
tremelimumab
overall survival
progression-free survival
Online Access:https://www.dovepress.com/plasma-growth-hormone-as-a-prognostic-biomarker-to-durvalumab-and-trem-peer-reviewed-fulltext-article-JHC

Internet

https://www.dovepress.com/plasma-growth-hormone-as-a-prognostic-biomarker-to-durvalumab-and-trem-peer-reviewed-fulltext-article-JHC

Similar Items